Firms will also develop specific diagnostic identification, scoring, and reporting software for future LabChip Dx instruments. Caliper Life Sciences and DxTerity Diagnostics entered into a ...

HOPKINTON, Mass., Nov. 2 Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of life sciences tools, today announced the availability of two new products that expand the LabChip GX product ...

Caliper Life Sciences, Inc. has launched the Caliper LabChip® EZ Reader™ Series, delivering a complete range of products for in-house kinase profiling. The series, which complements the existing ...

HOPKINTON, Mass., May 5 Caliper Life Sciences,Inc. (Nasdaq: CALP) today announced a collaboration with DiscoveRx Corporationthat enables functional cell-based G protein-coupled receptor (GPCR) ...

Firms will work together to expand range of SeePlex tests available for microfluidics-based system. Caliper Life Sciences and Seegene are teaming up to apply Seegene’s SeePlex™ multiplex diagnostic ...

Caliper Life Sciences, Inc. has introduced two microfluidics-based separations products, the LabChip® GX and LabChip GXII benchtop systems for automated, 1-D electrophoretic separations of protein, ...

HOPKINTON, Mass., Jan. 31, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. announced today that Caliper and Trinean, NV have agreed to a long-term, exclusive arrangement under which Caliper will ...

Caliper Life Sciences Inc. has agreed to work with DxTerity Diagnostics Inc. to develop and market DxTerity diagnostic assays that will run on Caliper's LabChip research instruments. Terms were not ...

Making its latest foray into the microfluidics ring, Hopkinton, Mass.-based Caliper Life Sciences http://www.caliperls.com has introduced the new LabChip 3000 Drug ...

HOPKINTON, Mass., Sept. 6, 2011 /PRNewswire/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP) today announced a collaboration with the Center for Genome Analysis at Yale University. As part of this ...

Caliper's LabChip instruments -- the LabChip 3000 and LabChip EZ Reader (R) series -- which have been adopted by 17 of the top 20 pharmaceutical and biotechnology companies, utilize proprietary ...